171 related articles for article (PubMed ID: 34772864)
1. Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.
Berndl F; Hassler MR
Curr Opin Urol; 2022 Jan; 32(1):48-53. PubMed ID: 34772864
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
[TBL] [Abstract][Full Text] [Related]
3. Genomic Characterization of Upper Tract Urothelial Carcinoma.
Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
[TBL] [Abstract][Full Text] [Related]
5. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis.
Rizzo A; Mollica V; Santoni M; Massari F
Clin Genitourin Cancer; 2022 Oct; 20(5):482-487. PubMed ID: 35858936
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
Fontugne J; Xylinas E; Krucker C; Dixon V; Groeneveld CS; Pinar U; Califano G; Bucau M; Verine J; Desgrandchamps F; Hermieu JF; Radvanyi F; Allory Y; Masson-Lecomte A
Mod Pathol; 2023 Nov; 36(11):100300. PubMed ID: 37558130
[TBL] [Abstract][Full Text] [Related]
9. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy.
Sfakianos JP; Gul Z; Shariat SF; Matin SF; Daneshmand S; Plimack E; Lerner S; Roupret M; Pal S
Eur Urol Oncol; 2021 Apr; 4(2):170-179. PubMed ID: 33386276
[TBL] [Abstract][Full Text] [Related]
10. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature.
Hassler MR; Bray F; Catto JWF; Grollman AP; Hartmann A; Margulis V; Matin SF; Roupret M; Sfakianos JP; Shariat SF; Faltas BM
Eur Urol; 2020 Aug; 78(2):209-220. PubMed ID: 32571725
[TBL] [Abstract][Full Text] [Related]
11. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.
Robinson BD; Vlachostergios PJ; Bhinder B; Liu W; Li K; Moss TJ; Bareja R; Park K; Tavassoli P; Cyrta J; Tagawa ST; Nanus DM; Beltran H; Molina AM; Khani F; Miguel Mosquera J; Xylinas E; Shariat SF; Scherr DS; Rubin MA; Lerner SP; Matin SF; Elemento O; Faltas BM
Nat Commun; 2019 Jul; 10(1):2977. PubMed ID: 31278255
[TBL] [Abstract][Full Text] [Related]
12. Differences in genomic profile of high-grade urothelial carcinoma according to tumor location.
Park CK; Cho NH
Urol Oncol; 2022 Mar; 40(3):109.e1-109.e9. PubMed ID: 34663543
[TBL] [Abstract][Full Text] [Related]
13. Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications.
Schneider B; Glass Ä; Jagdmann S; Hühns M; Claus J; Zettl H; Dräger DL; Maruschke M; Hakenberg OW; Erbersdobler A; Zimpfer A
Clin Genitourin Cancer; 2020 Oct; 18(5):e563-e572. PubMed ID: 32340874
[TBL] [Abstract][Full Text] [Related]
14. Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort.
Kullmann F; Strissel PL; Strick R; Stoehr R; Eckstein M; Bertz S; Wullich B; Sikic D; Wach S; Taubert H; Olbert P; Heers H; Lara MF; Macias ML; Matas-Rico E; Lozano MJ; Prieto D; Hierro I; van Doeveren T; Bieche I; Masliah-Planchon J; Beaurepere R; Boormans JL; Allory Y; Herrera-Imbroda B; Hartmann A; Weyerer V
J Clin Pathol; 2023 Feb; 76(2):126-132. PubMed ID: 34583948
[TBL] [Abstract][Full Text] [Related]
15. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review.
van Doeveren T; van de Werken HJG; van Riet J; Aben KKH; van Leeuwen PJ; Zwarthoff EC; Boormans JL
Urol Oncol; 2020 Jun; 38(6):590-598. PubMed ID: 32057596
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions.
Thouvenin J; Martínez Chanzá N; Alhalabi O; Lang H; Tannir NM; Barthélémy P; Malouf GG
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503152
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of molecular signatures in the urinary bladder and upper tract urothelial carcinomas: a prospective controlled clinical study.
Dawood EE; Awadalla A; Hashem A; Shokeir AA; Abdel-Aziz AF
J Egypt Natl Canc Inst; 2022 Nov; 34(1):47. PubMed ID: 36372809
[TBL] [Abstract][Full Text] [Related]
18. Genomics in upper tract urothelial carcinoma.
Kammerer-Jacquet SF; Mathieu R; Peyronnet B; Rioux-Leclercq N; Bensalah K
Curr Opin Urol; 2017 Jan; 27(1):35-40. PubMed ID: 27584028
[TBL] [Abstract][Full Text] [Related]
19. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Pal SK; Bajorin D; Dizman N; Hoffman-Censits J; Quinn DI; Petrylak DP; Galsky MD; Vaishampayan U; De Giorgi U; Gupta S; Burris HA; Soifer HS; Li G; Wang H; Dambkowski CL; Moran S; Daneshmand S; Rosenberg JE
Cancer; 2020 Jun; 126(11):2597-2606. PubMed ID: 32208524
[TBL] [Abstract][Full Text] [Related]
20. Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma.
De Lorenzis E; Albo G; Longo F; Bebi C; Boeri L; Montanari E
Genes (Basel); 2021 Feb; 12(3):. PubMed ID: 33668859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
